Clinical Trials Directory

Trials / Unknown

UnknownNCT05902884

New Biomarkers in Facioscapulohumeral Muscular Dystrophy, Multispectral Optoacoustic Tomography.

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

Facioscapulohumeral Muscular Dystrophy (FSHD) is one of the most frequent muscular dystrophies in the adulthood. Multi-spectral optoacoustic tomography (MSOT) is an innovative imaging technique able to non-invasively characterize the molecular composition of the muscle tissue. With this pilot study we will explore the performance of MSOT imaging in FSHD patients and correlate the findings with clinical and MRI data, with the final aim to identify new disease biomarkers.

Conditions

Interventions

TypeNameDescription
DEVICEMSOT Acuity EchoImaging of muscles applying Multi-spectral optoacoustic tomography (MSOT)

Timeline

Start date
2023-06-26
Primary completion
2023-09-30
Completion
2023-12-30
First posted
2023-06-15
Last updated
2023-07-06

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT05902884. Inclusion in this directory is not an endorsement.

New Biomarkers in Facioscapulohumeral Muscular Dystrophy, Multispectral Optoacoustic Tomography. (NCT05902884) · Clinical Trials Directory